BLRX News and Press, BioLineRx Ltd. From 11/03/22

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire Full data from pharma...

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization PR Newswire Company to accelerate availability to patients and maximize value through independent commercialization to well-defined U.S. transplant center community ...

BioLineRx ( NASDAQ: BLRX ) shares dropped 30% pre-market on Monday after the biopharmaceutical company announced a $15M securities offering. The firm entered into definitive agreements with several institutional investors for the issuance and sale of 13,636,365 of its ...

BioLineRx Announces $15 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , Sept. 19, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced...

BioLineRx ( NASDAQ: BLRX ) said it signed a $40M non-dilutive secured debt financing agreement with Kreos Capital. The first tranche of $10M was made available to BioLineRx upon execution of the agreement. The remaining $30M will be available in two additional tranches...

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital PR Newswire Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved TEL AVIV, Israel , Sep...

BioLineRx ( NASDAQ: BLRX ) submitted its new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for patients with multiple myeloma. The ...

BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization PR Newswire Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study Stem cell mobilization for bone marrow transpla...

BioLineRx Ltd. (BLRX) Q2 2022 Earnings Conference Call August 16, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer ...

biolinerx ( NASDAQ: BLRX ) is trading 9% lower as the company 's research and development costs and sales and marketing expenses rose. The company's Q2 loss of -$0.01 and beat estimates by $0.08. Sales and marketing expenses rose 250.9% Y/Y to $1.2M,&...